A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies in Patients at High Risk of Severe Forms of Covid-19
Latest Information Update: 06 Jun 2024
At a glance
- Drugs Adintrevimab (Primary) ; Bamlanivimab (Primary) ; Casirivimab/imdevimab (Primary) ; Cilgavimab/tixagevimab (Primary) ; Etesevimab (Primary) ; Sotrovimab (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Acronyms COVIMAB
Most Recent Events
- 06 Jul 2022 New trial record